Ichnos Glenmark Innovation & AbbVie ink exclusive global licensing agreement for ISB 2001: New York Saturday, July 12, 2025, 12:00 Hrs [IST] IGI Therapeutics SA, a wholly owned su ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Glenmark Pharma's exclusive licensing deal with AbbVie for ISB-2001 could be transformative, offering significant upside ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

Shares of Glenmark Pharmaceuticals Ltd ended 14.51 per cent higher on Friday after the firm announced signing an up to USD 2-billion deal with AbbVie to commmercialise its underdevelopment drug aimed ...

The investment landscape is shifting as companies show resilience and innovation, prompting investors to reassess portfolios. AbbVie, Boeing, Oracle, and Joby Aviation mentioned as potential ...

Regardless of the bearish sentiment prevailing across the Indian stock market today, Glenmark Pharma shares skyrocketed 16% ...

Glenmark Pharmaceuticals Ltd's shares soared over 14% after announcing a deal with AbbVie worth up to USD 2 billion. The ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to ...

On Thursday, IGI Therapeutics SA, a subsidiary of Glenmark, signed an exclusive license agreement with American drugmaker AbbVie to develop, manufacture, and commercialise the cancer drug ISB 2001.